スリンダク (Synonyms: Sulindac; MK-231)

Name: Sulindac
Brand: MedChemExpress
SKU: HY-B0008
Rating: 4.5 (0 reviews)

製品番号: HY-B0008 純度: 99.68%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

スリンダク 構造式

CAS 番号 : 38194-50-2

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 86	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 86	在庫あり	Estimated Time of Arrival: December 31
Solid
100 mg	$79	在庫あり	Estimated Time of Arrival: December 31
500 mg	$125	在庫あり	Estimated Time of Arrival: December 31
1 g		お問い合わせ
5 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

Other Forms of Sulindac:

Sulindac-d₃ 在庫あり
Sulindac sulfide 在庫あり
Sulindac sulfone 在庫あり
Sulindac sodium お問い合わせ
Sulindac (Standard) お問い合わせ

NF-κB アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]

COX-2

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
BXPC-3	IC₅₀	980 3 Compound: SUL	Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
COLO 320	IC₅₀	>200 3 Compound: a	Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
BXPC-3	IC₅₀	980 3 Compound: SUL	Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
BXPC-3	IC₅₀	980 3 Compound: SUL	Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
HeLa	IC₅₀	>50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HT-29	IC₅₀	1729 3 Compound: Sulindac	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
COLO 320	IC₅₀	> 200 3 Compound: a	Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HT-29	IC₅₀	800 3 Compound: SUL	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
COLO 320	IC₅₀	> 200 3 Compound: a	Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay Cytotoxicity against human COLO320 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
Jurkat	IC₅₀	699 3 Compound: SUL	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	965 3 Compound: SUL	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
MCF7	IC₅₀	>50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HT-29	IC₅₀	1729 3 Compound: Sulindac	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
HT-29	IC₅₀	800 3 Compound: SUL	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
MDCK	IC₅₀	300 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells	[PMID: 11844707]
MDCK	IC₅₀	320 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line	[PMID: 11844707]
Jurkat	IC₅₀	699 3 Compound: SUL	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MIA PaCa-2	IC₅₀	300 3 Compound: Sulindac	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MIA PaCa-2	IC₅₀	>200 3 Compound: a	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
NIH3T3	IC₅₀	200 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts	[PMID: 11844707]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	965 3 Compound: SUL	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
RBL-1	IC₅₀	>100 3 Compound: 8	Inhibition of 5-lipoxygenase in intact RBL-1 cell line Inhibition of 5-lipoxygenase in intact RBL-1 cell line	[PMID: 2115586]
MDCK	IC₅₀	300 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells	[PMID: 11844707]
HT-29	IC₅₀	1729 3 Compound: Sulindac	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
REF	IC₅₀	100 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF) Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF)	[PMID: 11844707]
MDCK	IC₅₀	320 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line	[PMID: 11844707]
HT-29	IC₅₀	800 3 Compound: SUL	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
Sf21	IC₅₀	226 3 Compound: Sulindac	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
Sf21	IC₅₀	87.5 3 Compound: Sulindac	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
MIA PaCa-2	IC₅₀	> 200 3 Compound: a	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	800 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells	[PMID: 11844707]
MIA PaCa-2	IC₅₀	300 3 Compound: Sulindac	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
NIH3T3	IC₅₀	200 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts	[PMID: 11844707]
HeLa	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
REF	IC₅₀	100 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF) Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF)	[PMID: 11844707]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
Jurkat	IC₅₀	699 3 Compound: SUL	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	965 3 Compound: SUL	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	800 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells	[PMID: 11844707]
MCF7	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MDCK	IC₅₀	300 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK cells	[PMID: 11844707]
MDCK	IC₅₀	320 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line Anti-proliferative activity was evaluated by its ability to inhibit proliferation of MDCK-f3 (Madin-Darby canine kidney f3) cell line	[PMID: 11844707]
MIA PaCa-2	IC₅₀	300 3 Compound: Sulindac	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35439009]
MIA PaCa-2	IC₅₀	> 200 3 Compound: a	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by WST-1 assay	[PMID: 20801552]
NIH3T3	IC₅₀	200 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts Anti-proliferative activity was evaluated by its ability to inhibit proliferation of murine NIH3T3 fibroblasts	[PMID: 11844707]
RBL-1	IC₅₀	> 100 3 Compound: 8	Inhibition of 5-lipoxygenase in intact RBL-1 cell line Inhibition of 5-lipoxygenase in intact RBL-1 cell line	[PMID: 2115586]
REF	IC₅₀	100 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF) Anti-proliferative activity was evaluated by its ability to inhibit proliferation of rat embryonic fibroblasts (REF)	[PMID: 11844707]
SW480	IC₅₀	800 3 Compound: Sulindac	Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells Anti-proliferative activity was evaluated by its ability to inhibit proliferation of SW480 cells	[PMID: 11844707]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	> 50 3 Compound: Sulindac	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
Sf21	IC₅₀	226 3 Compound: Sulindac	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	87.5 3 Compound: Sulindac	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

体外実験

Sulindac (MK-231) (500 μM, 48 h) is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors^[1].
Sulindac (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells^[1].
Sulindac (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac and SIRT1 upregulation promoted TGF-β1-induced EMT^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	A549 cells
Concentration:	500 μM
Incubation Time:	48 h
Result:	Inhibit transforming growth factor (TGF)-β1-induced epithelial-mesenchymal transition in A549 cells.

Immunofluorescence^[1]

Cell Line:	A549 cells
Concentration:	500 μM
Incubation Time:	48 h
Result:	Reversed SIRT-1 expression by TGF-β1 and inhibited the TGF-β1-induced cadherin switch.

Cell Migration Assay ^[1]

Cell Line:	A549 cells
Concentration:	500 μM
Incubation Time:	48 h
Result:	Inhibited migration, decreased resistance co-treatment with TGF-β1.

Cell Invasion Assay^[1]

Cell Line:	A549 cells
Concentration:	500 μM
Incubation Time:	40 h; 48 h
Result:	Could effectively inhibit the TGF- β1-induced increase in invasion by lung cancer cells.

体内実験

Sulindac (MK-231) (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume and increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy^[2].
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P^[2].
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy^[2].
Sulindac (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CT26 syngeneic mouse tumor model^[2]
Dosage:	15 mg/kg; 7.5 mg/kg
Administration:	15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)
Result:	Downregulated PD-L1 through the blockade of NF-κB signaling and modulate the response of pMMR CRC to anti-PD-L1 immunotherapy. Cound effectively inhibit PD-L1 with no significant systematic toxicity.

分子量

356.41

分子式

C₂₀H₁₇FO₃S

CAS 番号

38194-50-2

Appearance

Solid

Color

White to yellow

SMILES

O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (140.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8058 mL	14.0288 mL	28.0576 mL
5 mM	0.5612 mL	2.8058 mL	5.6115 mL
10 mM	0.2806 mL	1.4029 mL	2.8058 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.68%

Select Batch:

データシート (282 KB) SDS (644 KB)

COA (254 KB) HNMR (138 KB) LCMS (95 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227. [Content Brief]

[2]. Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20(7):1295-1304. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8058 mL	14.0288 mL	28.0576 mL	70.1439 mL
	5 mM	0.5612 mL	2.8058 mL	5.6115 mL	14.0288 mL
	10 mM	0.2806 mL	1.4029 mL	2.8058 mL	7.0144 mL
	15 mM	0.1871 mL	0.9353 mL	1.8705 mL	4.6763 mL
	20 mM	0.1403 mL	0.7014 mL	1.4029 mL	3.5072 mL
	25 mM	0.1122 mL	0.5612 mL	1.1223 mL	2.8058 mL
	30 mM	0.0935 mL	0.4676 mL	0.9353 mL	2.3381 mL
	40 mM	0.0701 mL	0.3507 mL	0.7014 mL	1.7536 mL
	50 mM	0.0561 mL	0.2806 mL	0.5612 mL	1.4029 mL
	60 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1691 mL
	80 mM	0.0351 mL	0.1754 mL	0.3507 mL	0.8768 mL
	100 mM	0.0281 mL	0.1403 mL	0.2806 mL	0.7014 mL

Sulindac Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

スリンダク (Synonyms: Sulindac; MK-231)

カスタマーレビュー

Other Forms of Sulindac:

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NF-κB アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Sulindac Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

スリンダク (Synonyms: Sulindac; MK-231)

カスタマーレビュー

Other Forms of Sulindac:

スリンダク 関連抗体

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NF-κB アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

スリンダク 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Sulindac Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report

スリンダク関連抗体

スリンダク関連抗体